Safety Study of MGA271 in Refractory Cancer

Sponsor

MacroGenics (Industry)

Overall Status

Completed

CT.gov ID

NCT01391143

Collaborator

(none)

179

Enrollment

Locations

Arm

93.6

Duration (Months)

14.9

Patients Per Site

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer. The study will also evaluate how long MGA271 stays in the blood and how long it takes for it to leave the body, what is the highest dose that can safely be given, and whether it may have an effect on tumors.

Condition or Disease	Intervention/Treatment	Phase
Prostate Cancer Melanoma Renal Cell Carcinoma Triple-negative Breast Cancer Head and Neck Cancer Bladder Cancer Non-small Cell Lung Cancer	Biological: MGA271	Phase 1

Detailed Description

An open-label, multi-dose, single-arm, multi-center, Phase 1, dose-escalation study will be conducted to define the toxicity profile, maximum tolerated dose (MTD), pharmacokinetics (PK), immunogenicity, and potential antitumor activity of MGA271 in patients with refractory cancer that expresses B7-H3.

In the initial segments of the study, patients will be monitored for a minimum of four weeks after administration of the final dose of MGA271. Study assessments will include adverse event (AE) monitoring, electrocardiogram (ECG) monitoring, PK analysis of serum MGA271, determination of the serum concentration of soluble MGA271 and tumor markers, and an assessment of potential anti-MGA271 antibody [human anti-human antibody (HAHA)] response.

Tumor response assessments using Study Day 43 CT scans or MRI will be performed approximately six weeks after the first MGA271 dose for each patient. Patients with evidence of clinical benefit (partial or complete response or stable disease by RECIST or RANO Response criteria) will be allowed to continue therapy at the same dose, or at a reduced dose if warranted by dose limiting toxicity (DLT) or significant AE in Cycle 1. Subsequent cycles which will begin on Study Day 50 will consist of MGA271 administration on Study Days 1, 8, and 15 of each 28-day cycle, with tumor evaluation every other cycle. Responding patients may receive continued antibody therapy until evidence of progression of disease is documented or the patient experiences DLT.

In the Expansion Segment of the study, patients will receive weekly, uninterrupted infusions with an initial response assessment at 8 weeks. Tumor evaluation will be carried out by both RECIST and immune-related response criteria (irRC).

Study Design

Study Type:

Interventional

Actual Enrollment :

179 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer

Study Start Date :

Jul 1, 2011

Actual Primary Completion Date :

Apr 18, 2019

Actual Study Completion Date :

Apr 18, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: MGA271 Fc-optimized, humanized monoclonal antibody	Biological: MGA271 Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression. Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles.

Arm

Intervention/Treatment

Experimental: MGA271

Fc-optimized, humanized monoclonal antibody

Biological: MGA271

Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression. Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles.

Outcome Measures

Primary Outcome Measures

Safety [Study Day 50 or 28 days after last infusion]
Adverse events, serious adverse events, ECG monitoring, adrenal function monitoring, monitoring for development of anti-drug antibodies

Secondary Outcome Measures

Maximum tolerated dose [Study Day 50 or 28 days after last infusion]

Other Outcome Measures

Tumor response [Every 8 weeks]
Efficacy will be assessed every 8 weeks in the Expansion Segment according to immune-related response criteria

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically or cytologically confirmed carcinoma (prostate cancer, renal cell carcinoma, head and neck cancer, triple-negative breast cancer, bladder cancer, non-small cell lung cancer) or melanoma that overexpresses B7-H3.
Progressive disease during or after last treatment regimen.
Appropriate treatment history for histological entity.
ECOG Performance Status <= 1.
Life expectancy >= 3 months.
Measurable disease or evaluable disease with relevant tumor marker elevation.
Acceptable laboratory parameters and adequate organ reserve.

Exclusion Criteria:

Major surgery or trauma within four weeks before enrollment.
Known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the drug formulation.
Grade 3 colitis, hepatitis, pneumonitis uveitis, myocarditis, myositis, CNS toxicity or autoimmune related neuromuscular toxicity such as myasthenia gravis associated with the administration of an immune checkpoint inhibitor
Second primary malignancy that has not been in remission for greater than 3 years. Treated non-melanoma skin cancer, cervical carcinoma in situ on biopsy, or squamous intraepithelial lesion on PAP smear, localized prostate cancer (Gleason score < 6), or resected melanoma in situ are exceptions and do not require a 3 year remission.
Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within four weeks of enrollment. Patients requiring any oral antiviral, fungal, or bacterial therapy must have completed treatment within one week of enrollment.
Vaccination within 2 weeks of enrollment (except for annual flu vaccine).
History of chronic or recurrent infections that require continual use of antiviral, antifungal, or antibacterial agents.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	UCLA Hematology-Oncology Clinic	Los Angeles	California	United States	90095
2	Yale Cancer Center	New Haven	Connecticut	United States	06520
3	Moffitt Cancer Center	Tampa	Florida	United States	33612
4	The University of Chicago	Chicago	Illinois	United States	60637
5	Norton Cancer Institute	Louisville	Kentucky	United States	40202
6	University of Maryland	Baltimore	Maryland	United States	21201
7	Neely Center for Clinical Cancer Research, Tufts Medical Center	Boston	Massachusetts	United States	02111
8	Massachusetts General Hospital Cancer Center	Boston	Massachusetts	United States	02114
9	Dana Farber Cancer Institute	Boston	Massachusetts	United States	02215
10	Carolina Biooncology Institute	Huntersville	North Carolina	United States	28078
11	Hospital of the University of Pennsylvania/Abramson Cancer Center	Philadelphia	Pennsylvania	United States	19104
12	Sarah Cannon Research Institute	Nashville	Tennessee	United States	37203